Download PDF
Exp Clin Endocrinol Diabetes 2021; 129(02): 112-117
DOI: 10.1055/a-0956-1919
Article

Adherence, Attitudes and Beliefs of Growth Hormone Deficient Patients – A Questionnaire-based Cohort Study

Felix Amereller
1   Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, München, Germany
,
Katharina Schilbach
1   Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, München, Germany
,
Jochen Schopohl
1   Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, München, Germany
,
Sylvère Störmann
1   Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, München, Germany
› Author Affiliations Funding: JS has received lecture fees honoraria and grants from Novartis, Ipsen and Pfizer and grants from Chiasma and OPKO Health. He is also a consultant for Ipsen and Novartis. SS has received lecture fees honoraria and grants from Novartis, Ipsen and Pfizer.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Introduction GHD is a chronic and systemic disease requiring daily replacement of growth hormone (GHRT). Adherence and attitudes of adult GHD patients are not well known. We sought to assess patients’ knowledge of growth hormone deficiency (GHD) in association with treatment adherence and attitudes regarding available and upcoming treatment options.

Methods We performed a cross-sectional survey with a custom-made questionnaire at a single centre assessing data on demographics, knowledge of GHD, adherence and attitudes towards GHRT.

Results Of 106 eligible patients actively followed for GHD 70 returned the completed survey (return-rate 66%, 34 m/36 f; age 56±14 years). 46 patients were actively treated, but almost one third (n=24) refused GHRT. 12 patients had participated in clinical trials with LAGH (long-acting growth hormone). Overall, patients with GHRT showed good adherence. Patients refusing GHRT mostly feared side effects and/or had a lack of information/perceived effect. Disease knowledge and level of education were higher in treated than untreated patients (p=0.023/0.017). Only 36% of respondents would initiate treatment with LAGH. Patients with prior LAGH experience and patients with childhood-onset GHD were more likely to adopt LAGH (p=0.048/0.031).

Discussion Most often, misinformation causes patients to refuse GHRT. Possibly the understanding of their condition and consequences of non-treatment is limited. To improve adherence more focused educational and behavioural strategies may be needed. Willingness to begin a therapy with LAGH was lower than expected (36%). The reasons for reluctance against LAGH need to be elucidated.

Key words

treatment adherence - growth hormone deficiency - growth hormone therapy - recombinant growth hormone - health knowledge

Supplementary Material



Publication History

Received: 28 January 2019
Received: 29 May 2019

Accepted: 11 June 2019

Article published online:
02 July 2019

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Lin E, Wexler TL, Nachtigall L. et al. Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly. Clin Endocrinol (Oxf) 2012; 77: 430-438
    CrossrefPubMedGoogle Scholar
  • 2 Gaillard R-C, Mattsson AF, Akerblad A-C. et al. Overall and cause-specific mortality in growth hormone-deficient adults on growth hormone replacement. Eur J Endocrinol 2012; 1-36
    PubMedGoogle Scholar
  • 3 Berryman DE, List EO. Growth Hormone’s effect on adipose tissue: Quality versus quantity. Int J Mol Sci 2017; 18: 1-28
    CrossrefPubMedGoogle Scholar
  • 4 Crespo I, Santos A, Webb SM. Quality of life in patients with hypopituitarism. Curr Opin Endocrinol Diabetes Obes 2015; 22: 306-312
    CrossrefPubMedGoogle Scholar
  • 5 Elbornsson M, Horvath A, Götherström G. et al. Seven years of growth hormone (GH) replacement improves quality of life in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol 2017; 176: 99-109
    CrossrefPubMedGoogle Scholar
  • 6 Ho KK. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: A statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, J. Eur J Endocrinol 2007; 157: 695-700
    CrossrefPubMedGoogle Scholar
  • 7 Kapoor RR, Burke SA, Sparrow SE. et al. Monitoring of concordance in growth hormone therapy. Arch Dis Child 2008; 93: 147-148
    CrossrefPubMedGoogle Scholar
  • 8 Cutfield WS, Derraik JGB, Gunn AJ. et al. Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS One 2011; 6: 5-7
    CrossrefPubMedGoogle Scholar
  • 9 Bozzola M, Pagani S, Iughetti L. et al. Adherence to growth hormone therapy: A practical approach. Horm Res Paediatr 2014; 81: 331-335
    CrossrefPubMedGoogle Scholar
  • 10 Hartmann K, Ittner J, Müller-Rossberg E. et al. Growth hormone treatment adherence in prepubertal and pubertal children with different growth disorders. Horm Res Paediatr 2013; 80: 1-5
    CrossrefPubMedGoogle Scholar
  • 11 Haverkamp F, Johansson L, Dumas H. et al. Observations of nonadherence to recombinant human growth hormone therapy in clinical practice. Clin Ther 2008; 30: 307-316
    CrossrefPubMedGoogle Scholar
  • 12 Smith SL, Hindmarsh PC, Brook CG. Compliance with growth hormone treatment – are they getting it?. Arch Dis Child 1993; 68: 91-93
    CrossrefPubMedGoogle Scholar
  • 13 Oyarzabal M, Aliaga M, Chueca M. et al. Multicentre survey on compliance with growth hormone therapy: What can be improved?. Acta Paediatr Int J Paediatr 1998; 87: 387-391
    CrossrefPubMedGoogle Scholar
  • 14 Fisher BG, Acerini CL. Understanding the growth hormone therapy adherence paradigm: A systematic review. Horm Res Paediatr 2013; 79: 189-196
    CrossrefPubMedGoogle Scholar
  • 15 Rosenfeld R, Bakker B. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract 2008; 14: 143-154
    CrossrefPubMedGoogle Scholar
  • 16 Zaninelli DCT, Meister LHF, Radominski RB. et al. Eficácia, segurança e aderência ao tratamento de longo prazo com hormônio de crescimento (GH) em adultos com deficiência de GH. Arq Bras Endocrinol Metabol 2008; 52: 879-888
    CrossrefPubMedGoogle Scholar
  • 17 Giavoli C, Cappiello V, Porretti S. et al. Growth hormone therapy in GH-deficient adults: Continuous vs. alternate-days treatment. Horm Metab Res 2003; 35: 557-561
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Amato G, Mazziotti G, Di Somma C. et al. Recombinant Growth Hormone (GH) Therapy in GH-deficient adults: A long-term controlled study on daily versus thrice weekly injections. J Clin Endocrinol Metab 2000; 85: 3720-3725
    CrossrefPubMedGoogle Scholar
  • 19 Johansson JO, Wirén L, Oscarsson J. et al. Growth hormone (GH) replacement in GH-deficient adults: A crossover trial comparing the effect on metabolic control, well-being and compliance of three injections per week versus daily injections. Growth Horm IGF Res 2003; 13: 306-315
    CrossrefPubMedGoogle Scholar
  • 20 Pincelli AI, Bragato R, Scacchi M. et al. Three weekly injections (TWI) of low-dose growth hormone (GH) restore low normal circulating IGF-I concentrations and reverse cardiac abnormalities associated with adult onset GH deficiency (GHD). J Endocrinol Invest 2003; 26: 420-428
    CrossrefPubMedGoogle Scholar
  • 21 Abdi L, Sahnoun-Fathallah M, Morange I. et al. A monocentric experience of growth hormone replacement therapy in adult patients. Ann Endocrinol (Paris) 2014; 75: 176-183
    CrossrefPubMedGoogle Scholar
  • 22 Christiansen JS, Backeljauw PF, Bidlingmaier M. et al. Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. Eur J Endocrinol 2016; 174: C1-C8
    CrossrefPubMedGoogle Scholar
  • 23 Auer MK, Stieg MR, Hoffmann J. et al. et al. Is Insulin-like-growth-factor-I a good marker for treatment adherence in growth-hormone deficiency in adulthood?. Clin Endocrinol (Oxf) 2016; 84: 862-869
    CrossrefPubMedGoogle Scholar
  • 24 Lam WY, Fresco P. Medication adherence measures: An overview. Biomed Res Int 2015; 2015: 217047
    PubMedGoogle Scholar
  • 25 Nguyen TMU, Caze A La, Cottrell N. What are validated self-report adherence scales really measuring?: A systematic review. Br J Clin Pharmacol 2014; 77: 427-445
    CrossrefPubMedGoogle Scholar
  • 26 Morisky DE, Ang A, Krousel-Wood M. et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 2008; 10: 348-354
    CrossrefPubMedGoogle Scholar
  • 27 Kim MT, Hill MN, Bone LR. et al. Development and testing of the Hill-Bone compliance to high blood pressure therapy scale. Prog Cardiovasc Nurs 2000; 15: 90-96
    CrossrefPubMedGoogle Scholar
  • 28 Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 2000; 42: 241-247
    CrossrefPubMedGoogle Scholar
  • 29 DiMatteo MR, Haskard KB, Williams SL. Health beliefs, disease severity, and patient adherence. Med Care 2007; 45: 521-528
    CrossrefPubMedGoogle Scholar
  • 30 Nieuwlaat R, Wilczynski N, Navarro T. et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2014; 2-4
    PubMedGoogle Scholar
  • 31 Acerini CL, Wac K, Bang P. et al. Optimizing patient management and adherence for children receiving growth hormone. Front Endocrinol (Lausanne) 2017; 8: 1-6
    CrossrefPubMedGoogle Scholar
  • 32 Vermiere E, Hearnshaw H, Van Royen PD. Patient Adherence to Treatment: Three decades of research: A comprehensive review. J Clin Pharm Ther 2001; 26: 331-342
    CrossrefPubMedGoogle Scholar
  • 33 Joosten EAG, DeFuentes-Merillas L, de Weert GH. et al. Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom 2008; 77: 219-226
    CrossrefPubMedGoogle Scholar
  • 34 Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005; 80: 856-861
    CrossrefPubMedGoogle Scholar
  • 35 Cramer J, Lynch N, Gaudin A. et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom. Clin Ther 2006; 28: 1686-1694
    CrossrefPubMedGoogle Scholar
  • 36 Bartl R, Götte S, Hadji P. et al. Adhärenz mit täglichen und wöchentlichen oralen bisphosphonaten in der osteoporosetherapie. Dtsch Medizinische Wochenschrift 2006; 131: 1257-1262
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Osterberg L, Blaschke T, L. O. et al. Adherence to medication. N Engl J Med 2005; 353: 487-497
    CrossrefPubMedGoogle Scholar
  • 38 Boguszewski CL. Update on GH therapy in adults. F1000Research 2017; 6: 2017
    CrossrefPubMedGoogle Scholar
  • 39 Caicedo A, Rosenfeld R. Challenges and future for the delivery of growth hormone therapy. Growth Horm IGF Res 2017; 1-5
    PubMedGoogle Scholar